Development of an AlphaLISA Protein-Protein Interaction Assay to Screen for Re-Purposed Drugs as Targeted Disruptors

BMG Logo 2


The threat of global pandemics emphasises the quick identification of the cause of an emerging disease and its route of infection. Once these characteristics are defined, drug repurposing offers to identify previously approved drugs that might be applicable and quickly approvable for the treatment of the new disease. 

Download this app note to discover an assay that can:

  • Screen targeted disruptors of the interaction between SARS-CoV-2 and the human ACE2 protein 
  • Reduce the frequency of false positives 
  • Identify drugs that can be re-purposed for the treatments of SARS-CoV-2